GLP-1 drugs are predicted to become the top-selling pharmaceutical class ever, with projected US sales of $150 billion by 2030. I have written multiple articles on GLP-1 drugs, highlighting their ...

Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...

The constant evolution of new COVID-19 variants makes it critical for clinicians to have multiple therapies in their arsenal for treating drug-resistant infections. Researchers have now discovered ...

Scientists have identified a new anti-ageing drug class that works by acting on a key gut bacteria process, an advance that may lead to ways to prolong lifespan in humans. Researchers from Queen Mary ...